SeaSpine reported its fourth quarter and full-year 2017 financial results.
Here are eight takeaways from the company's fourth quarter.
1. The company saw revenue of $34 million, reflecting a 4.5 percent year-over-year increase.
2. In the U.S., SeaSpine reported revenue of $31.2 million, a 4.8 percent year-over-year jump.
3. Orthobiologics revenue reached $18.1 million, an 8.8 percent year-over-year boost.
4. SeaSpine reported spinal implants revenue reached $15.9 million, which didn't register a significant change year over year.
5. The company saw $2.8 million in international revenue, which is a 1 percent year-over-year increase.
6. The company's gross margin was 63.3 percent, compared to 58.6 percent in the fourth quarter of 2016.
7. SeaSpine reported net loss of $7.5 million, compared to $9.8 million in the same period the year prior.
8. The company had $10.8 million in cash and cash equivalents on Dec. 31, 2017.
The following reflects the company's full-year 2017 financial results.
9. Full-year revenue reached $131.8 million, a 2.3 percent jump over 2016.
10. U.S. revenue hit $118.4 million, a 1.4 percent boost compared to 2016.
11. The orthobiologics revenue reached $69.1 million, a 4.4 percent jump from the year prior.
12. Spinal implant revenue totaled $62.7 million, a stagnant result compared to the year prior.
13. SeaSpine's gross margin was 60.7 percent in 2017.
14. The company had a net loss of $32.1 million, compared to $43.2 million in 2016.
SeaSpine anticipates full-year 2018 revenue to land between $135 million and $139 million.
More articles on devices:
Wright Medical reports $217.6M in Q4 sales: 6 takeaways
DePuy Synthes, Stryker, NuVasive & more: 12 device company notes
Ortho Sales Partners forming orthopedics and spine divisions, announces two executive additions: 4 things to know